Previous 10 | Next 10 |
Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for ...
Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, April 29, 2021, the Company will release financial results for the fourth quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, April 29, 2021 at 8:00 a.m. ET. Michael R. Minogue, ...
Abiomed (NASDAQ: ABMD) and Guardant Health (NASDAQ: GH) both sport market caps just north of $13 billion, but these companies represent very different ways to invest in healthcare stocks for the next decade. Abiomed is the maker of Impella, a temporarily implanted de...
According to an update posted on the federal register for clinical trials, Abbott ([[ABT]] +0.2%) has suspended the recruitment for SHIELD II clinical trial citing reports of ‘decreased impeller speed at the end of a procedure.’The randomized trial targeting to enroll 716 partic...
Abiomed (NASDAQ: ABMD) shares have tripled in value over the past five years. That's as the company brought its heart pumps to more and more patients. And recently, Abiomed even has become a player in the coronavirus market. The U.S. Food and Drug Administration has authorized its p...
Fast-growing Align Technology has a premium product thanks to its intellectual property in orthodontic treatment. The company is the world’s biggest producer of custom 3D printed materials giving patients more discreet treatments. Addressable market has grown from 300m to 5...
Following consultation with its notified body, MEDCERT GmbH, Abiomed is introducing the single access procedure with Impella CP introducer sheaths for the treatment of heart disease in Europe. This press release features multimedia. View the full release here: https://www.business...
Abiomed (NASDAQ: ABMD) announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors, effective immediately. Dr. Rolle will serve as a member of the Governance and Nominating Committee and Regulatory and Compliance Committee of the board. With the appointment of Dr...
High-scoring, high short-interest stocks that can benefit from ongoing short covering by hedge funds as they reduce single stock risk. Institutional quality stocks with potential catalysts that support ongoing short covering, rather than flash-in-the-pan volatility. Ideas across a...
Moleculin Biotech (MBRX) -21% on launch of public offering.NTN Buzztime (NTN) -16%.PEDEVCO (PED) -13% after pricing stock offering.Ocugen (OCGN) -14%.Voyager Therapeutics (VYGR) -13% on termination of Parkinson’s collaboration with Neurocrine Bio.Titan Med...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...